Overview
InspireMD Q2 revenue rises 2.3%, beating analyst expectations, per LSEG data
Net income for Q2 missed analyst expectations, per LSEG data
Co received FDA approval and launched CGuard Prime in U.S. market
Outlook
Company plans to launch CGuard Prime in Europe in Q3
InspireMD focuses on scaling operations post-U.S. launch
Company aims to establish CGuard as standard for carotid disease
Result Drivers
FDA APPROVAL - Received FDA approval for CGuard Prime carotid stent system, driving U.S. market launch
EXCHANGE RATES - Revenue positively impacted by exchange rates, offsetting decreased revenue from Russia
OPERATING EXPENSES - Increased due to U.S. sales force expansion and CGuard Prime launch preparation
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $1.78 mln | $1.52 mln (2 Analysts) |
Q2 Net Income | Miss | -$13.15 mln | -$12.90 mln (2 Analysts) |
Q2 Income From Operations | Beat | -$13.02 mln | -$13.10 mln (2 Analysts) |
Q2 Basic EPS | -$0.26 | ||
Q2 Gross Profit | $313,000 | ||
Q2 Operating Expenses | $13.33 mln |
Press Release: ID:nGNX4ZbSXW
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。